Treatment of metastatic colorectal carcinoma with lymphoblastoid interferon and 5-fluorouracil: Data of a phase II study

M. C. Barzacchi, M. T. Nobile, O. Sanguineti, M. R. Sertoli, S. Chiara, L. Repetto, G. Forno, A. Lavarello, R. Rosso

Research output: Contribution to journalArticle

Abstract

Many clinical trials have tested the combination of 5-fluorouracil and recombinant alfa interferons in metastatic colorectal carcinoma. The efficacy of 5-fluorouracil and lymphoblastoid interferon was evaluated in a phase II study in which 31 patients with advanced colorectal carcinoma were enrolled. 5-Fluorouracil was administered at the dose of 600 mg/sqm bolus weekly and lymphoblastoid interferon was given intramusculary at 3 million units every two days. All patients were evaluable for toxicity. Thirty patients were available for response: no complete response was recorded, three patients reached a partial response (10%), three a minor response (10%) and 18 progressed (59.4%). Overall median survival was 8 months. No grade IV toxicity was observed: in 2 patients grade III occurred and in 8 patients grade III fever and fatigue attributable to interferon developed. It appears that this combination does not yield better results than 5-fluorortracil alone.

Original languageEnglish
Pages (from-to)2147-2149
Number of pages3
JournalAnticancer Research
Volume14
Issue number5 B
Publication statusPublished - 1994

Keywords

  • 5-fluorouracil
  • Colorectal carcinoma
  • Lymphoblastoid interferon

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Treatment of metastatic colorectal carcinoma with lymphoblastoid interferon and 5-fluorouracil: Data of a phase II study'. Together they form a unique fingerprint.

  • Cite this

    Barzacchi, M. C., Nobile, M. T., Sanguineti, O., Sertoli, M. R., Chiara, S., Repetto, L., Forno, G., Lavarello, A., & Rosso, R. (1994). Treatment of metastatic colorectal carcinoma with lymphoblastoid interferon and 5-fluorouracil: Data of a phase II study. Anticancer Research, 14(5 B), 2147-2149.